NEW YORK, Aug. 21 - Sequenom has 18 busy months ahead of it.

The company today announced plans to acquire privately held Axiom Biotechnologies, which Sequenom said will help its nascent pharma division build some internal biology, assay, and drug-discovery muscle. Sequenom also said it will release a gaggle of new products and updated technology beginning in the third quarter and continuing into 2004.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.